You are here: Industry Insights > OncoImmune

News List

Merck agrees to buy biopharma firm OncoImmune for $425m pharmaceutical-technology
November 25, 2020
Merck (MSD) has signed a definitive agreement to acquire all outstanding shares of clinical-stage biopharmaceutical firm OncoImmune through a subsidiary, for an upfront payment of $425m in cash.
OncoImmune’s SACCOVID demonstrates significant therapeutic efficacy in Covid-19 trial pharmaceutical-business-review
September 30, 2020
OncoImmune announced that its investigational immunomodulator SACCOVID (CD24Fc) has demonstrated significant therapeutic efficacy in the phase III SAC-COVID clinical trial.
OncoImmune receives FDA approval for COVID-19 clinical trial pharmaceutical-business-review
April 14, 2020
OncoImmune has received a study-may-proceed letter from the FDA for its Phase III clinical trial testing the safety and efficacy of CD24Fc for the treatment of hospitalized COVID-19 patients (SAC-COVID).
OncoImmune gets approval to trial CD24Fc for Covid-19 in US pharmaceutical-technology
April 10, 2020
The US Food and Drug Administration (FDA) has approved for OncoImmune to conduct a Phase III clinical trial of CD24Fc to treat patients hospitalised with Covid-19.
OncoImmune Announces Completion of Phase II Trial americanpharmaceuticalreview
January 11, 2019
OncoImmune has completed its Phase IIa trial of CD24Fc for the Prevention of Acute GVHD Following Myeloablative Allogeneic HSCT.